Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...
The Central Bank said the firm failed to put effective arrangements in place to detect and report suspicious transactions.
In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...
In a report released yesterday, Sarah James from Cantor Fitzgerald maintained a Buy rating on Health Catalyst (HCAT – Research Report), with a ...